We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Corixa, a developer of immunotherapeutics, and Lorantis, a Cambridge, U.K.-based
immunotherapy company, have announced a joint collaboration in which the companies
will continue the development of a therapeutic hepatitis B vaccine, containing
Corixa's RC-529 adjuvant and Lorantis' CV-1831, a hepatitis B core antigen that
was previously owned by Apovia.
Millennium Pharmaceuticals has announced final results from the CLEAR Platelets
(Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets)
trial.
Indevus Pharmaceuticals has announced that a new study published in the January
edition of British Journal of Urology demonstrates that trospium chloride,
the active ingredient in Sanctura, marketed in the U.S. as a first-line therapy
for overactive bladder (OAB), had no effect on the sleep patterns of older subjects
(aged 51 to 65 years).
Xenova Group has announced preliminary 12-month findings from the second Phase
I trial of TA-NIC, the company's therapeutic vaccine being developed for the
treatment of nicotine addiction.
GenVec has announced the launch of a Phase IIb randomized, placebo-controlled
trial of its BIOBYPASS angiogen for the treatment of severe coronary artery
disease.
Human Genome Sciences has completed the enrollment and initial dosing of patients
in a Phase II clinical trial of HGS-ETR1 (mapatumumab) in advanced non-Hodgkin's
lymphoma.
Cellegy Pharmaceuticals has announced that 50 percent enrollment has been achieved
in the Savvy Phase III HIV prevention trial in Ghana based on current projected
enrollment.
QLT has announced that its partner Sosei has submitted a marketing authorization
application for SOT-375, a drug developed for prostate cancer, to the Japanese
Ministry of Health, Labour and Welfare (MHLW) requesting approval for marketing
in Japan.
Large Scale Biology (LSBC) and Icon Genetics (ICON) have entered into a collaborative
agreement to co-develop a biopharmaceutical product for a major therapeutic
market.